MetaCap

Nasus Pharma (NSRX) vs NextCure (NXTC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NextCure (NXTC) has outperformed Nasus Pharma (NSRX) over the past year, losing 38.6% versus a loss of 68.4%. NextCure is the larger company by market cap ($29.5 million vs $26.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NSRX-68.41%NXTC-38.63%
+42%-25%-91%
Nov 21, 20251 yearNov 20, 2026
NSRX-71.73%NXTC+26.10%
+188%+51%-85%
Aug 11, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NSRX versus NXTC key metrics
MetricNSRXNXTC
Share price$2.29$6.45
Market cap$26.82M$29.53M
1-day change-10.20%-4.87%
YTD return-74.97%-54.55%
1-year return-68.41%-38.63%
5-year return—-91.07%
EPS (TTM)$-1.20$-6.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.24B—
Net income (latest FY)$-5.86M$-55.84M
Operating margin-0.40%—
Net margin-0.47%—
52-week high$9.50$15.74
52-week low$1.98$1.55
Distance from 52-week high-75.89%-59.02%
Analyst consensusbuynone
Avg. price target upside+758.95%+210.08%
Average volume16.80K79.46K
Shares outstanding11.71M4.58M
Employees740
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NXTC has outperformed NSRX by 29.8 percentage points over the past year.

About Nasus Pharma

NSRX stock →

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About NextCure

NXTC stock →

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

NSRX vs NXTC FAQ

Which is bigger, Nasus Pharma or NextCure?

NextCure (NXTC) is larger, with a market capitalization of $29.53M compared with $26.82M for Nasus Pharma (NSRX).

Which stock has performed better over the past year, NSRX or NXTC?

NXTC returned -38.63% over the past 12 months, compared with -68.41% for NSRX (price return, excluding dividends). Past performance does not predict future results.

Are Nasus Pharma and NextCure in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons